HK1155160A1 - Compositions with and process for methylmorpholin-substituted pyrido - Google Patents

Compositions with and process for methylmorpholin-substituted pyrido

Info

Publication number
HK1155160A1
HK1155160A1 HK11109366.4A HK11109366A HK1155160A1 HK 1155160 A1 HK1155160 A1 HK 1155160A1 HK 11109366 A HK11109366 A HK 11109366A HK 1155160 A1 HK1155160 A1 HK 1155160A1
Authority
HK
Hong Kong
Prior art keywords
methylmorpholin
compositions
substituted pyrido
pyrido
substituted
Prior art date
Application number
HK11109366.4A
Other languages
English (en)
Inventor
Helen Blade
Gwydion Huw Churchill
Angela Charlotte Currie
Benjamin Charles Dobson
Peter Samuel Hynes
Martin Neal Kenworthy
Lyn Powell
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1155160A1 publication Critical patent/HK1155160A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK11109366.4A 2008-06-20 2011-09-05 Compositions with and process for methylmorpholin-substituted pyrido HK1155160A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7418808P 2008-06-20 2008-06-20
US15235009P 2009-02-13 2009-02-13
PCT/GB2009/050695 WO2009153597A2 (en) 2008-06-20 2009-06-18 Composition and process - 356

Publications (1)

Publication Number Publication Date
HK1155160A1 true HK1155160A1 (en) 2012-05-11

Family

ID=41051136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11109366.4A HK1155160A1 (en) 2008-06-20 2011-09-05 Compositions with and process for methylmorpholin-substituted pyrido

Country Status (27)

Country Link
US (1) US8198441B2 (es)
EP (1) EP2303875B1 (es)
JP (1) JP5607614B2 (es)
KR (1) KR101668497B1 (es)
CN (1) CN102137860B (es)
AR (1) AR072263A1 (es)
AU (1) AU2009261688B2 (es)
BR (1) BRPI0914912A2 (es)
CA (1) CA2728183C (es)
CL (1) CL2010001488A1 (es)
CO (1) CO6351729A2 (es)
CR (1) CR11859A (es)
DO (1) DOP2010000391A (es)
EA (1) EA019092B1 (es)
EC (1) ECSP10010696A (es)
ES (1) ES2398423T3 (es)
HK (1) HK1155160A1 (es)
IL (1) IL210074A (es)
MX (1) MX2010014230A (es)
MY (1) MY172107A (es)
NI (1) NI201000225A (es)
PE (1) PE20110147A1 (es)
SV (1) SV2010003770A (es)
TW (1) TWI441821B (es)
UY (1) UY31917A (es)
WO (1) WO2009153597A2 (es)
ZA (1) ZA201101861B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014912A (zh) * 2008-02-21 2011-04-13 阿斯利康(瑞典)有限公司 联合疗法238
EP2813506B1 (en) 2010-12-16 2016-05-25 F. Hoffmann-La Roche AG Tricyclic PI3K inhibitor compounds and methods of use
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
PT1210333E (pt) 1999-09-07 2005-03-31 Syngenta Participations Ag P-tolil-heterociclos como herbicidas
DE60144322D1 (de) 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7790709B2 (en) 2002-12-06 2010-09-07 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
WO2006135993A1 (en) 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
US20070128658A1 (en) * 2005-11-14 2007-06-07 Blackwell Helen E Fluorescent dyes, methods and uses thereof
WO2007060404A1 (en) * 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
LT2057156T (lt) * 2006-08-23 2017-05-25 Kudos Pharmaceuticals Limited 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
AU2008313504A1 (en) * 2007-10-15 2009-04-23 Astrazeneca Ab Combination 059

Also Published As

Publication number Publication date
EA019092B1 (ru) 2014-01-30
ZA201101861B (en) 2011-11-30
UY31917A (es) 2010-01-29
AU2009261688B2 (en) 2012-07-05
CR11859A (es) 2011-02-25
PE20110147A1 (es) 2011-03-26
DOP2010000391A (es) 2011-01-15
KR20110027789A (ko) 2011-03-16
ECSP10010696A (es) 2011-01-31
ES2398423T3 (es) 2013-03-19
TW201012818A (en) 2010-04-01
WO2009153597A2 (en) 2009-12-23
KR101668497B1 (ko) 2016-10-21
IL210074A0 (en) 2011-02-28
CA2728183C (en) 2016-10-25
CL2010001488A1 (es) 2011-07-15
MY172107A (en) 2019-11-14
IL210074A (en) 2015-07-30
AR072263A1 (es) 2010-08-18
AU2009261688A1 (en) 2009-12-23
JP2011524889A (ja) 2011-09-08
MX2010014230A (es) 2011-03-29
US20090318434A1 (en) 2009-12-24
CA2728183A1 (en) 2009-12-23
WO2009153597A3 (en) 2010-05-06
CN102137860A (zh) 2011-07-27
US8198441B2 (en) 2012-06-12
BRPI0914912A2 (pt) 2017-06-20
EP2303875A2 (en) 2011-04-06
EP2303875B1 (en) 2012-11-28
CO6351729A2 (es) 2011-12-20
CN102137860B (zh) 2013-08-28
EA201100063A1 (ru) 2011-10-31
JP5607614B2 (ja) 2014-10-15
NI201000225A (es) 2011-12-15
TWI441821B (zh) 2014-06-21
SV2010003770A (es) 2011-05-20

Similar Documents

Publication Publication Date Title
IL210153A0 (en) Nutrigenomics methods and compositions
HUE065114T2 (hu) Monoklórtrifluorpropén vegyületek és készítmények és eljárások azok alkalmazásával
HK1155160A1 (en) Compositions with and process for methylmorpholin-substituted pyrido
ZA201006944B (en) Compositions and methods for preparing and using same
GB0815872D0 (en) Novel method and compositions
IL212822A0 (en) Anti-cxcr1 compositions and methods
GB0819530D0 (en) Methods and compositions
IL210559A0 (en) Novel compositions and methods
ZA201007830B (en) Compositions and methods for immunity
IL210588A0 (en) Novel compositions and methods
GB0903299D0 (en) Composition and methods
GB0912468D0 (en) Composition and method
GB0817585D0 (en) Novel compositions and methods
GB0901494D0 (en) Compositions and Methods
GB0901667D0 (en) Composition and method
GB0811250D0 (en) Methods and compositions
EP2516649A4 (en) NOVEL PNEUMOVIRUS COMPOSITIONS AND METHODS OF USE
GB0807102D0 (en) Process and composition
GB0807336D0 (en) Composition and process
GB0912714D0 (en) Composition and process
GB0803464D0 (en) Methods and compositions
GB0818399D0 (en) Methods and compositions
GB0816534D0 (en) Compositions and methods
GB0811152D0 (en) Methods and compositions
GB0906693D0 (en) Composition and method

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210618